Document Detail

Low bone mineral density in adolescents with beta-thalassemia.
MedLine Citation:
PMID:  16339698     Owner:  NLM     Status:  MEDLINE    
The pervasiveness of low bone mass (LBM) in beta-thalassemia (Thal) patients (pts) is escalating as the average life expectancy of these pts increases. Adolescence is a period of substantial bone accrual, which is crucial for future bone strength. Studies of LBM are prevalent among adults with Thal. However, limited information exists about bone accrual and LBM in adolescents with the disease. Thirty-one pts with beta-Thal (26 Thal major [TM], 5 Thal intermedia [TI]), aged 9-20 years (mean: 15.3 years), 14 males and 17 females, underwent measurement of spinal bone mineral density (BMD) by DEXA (Lunar, Prodigy). Height, weight, body mass index, and Tanner stage were assessed at the time of the BMD measurement. A total of 16.1% of the patients had normal bone mass (Z > or = -1), 22.6% had reduced bone mass (Z = -1 to -2), and 61.3% had low bone mass (Z < or = -2). BMD Z correlated with height and weight Z scores. Some 53.9% of subjects had normal gonadal function and 46.1% had induced puberty with gonadal steroids. BMD Z significantly worsened with age (P < .0001). However, there was no difference in the LBM prevalence between subjects with normal versus those with induced puberty: BMD Z was -2 or less in 71.4% of subjects with normal puberty versus 66.7% in those with induced puberty. Our results indicate a high prevalence of LBM among adolescents with Thal regardless of adequate transfusion and chelation regimens. Bone accrual was found to be suboptimal in adolescents with normal or induced puberty. Thus, calcium and vitamin D supplementation with antiresorptive therapies should be evaluated in the adolescent Thal pt with close monitoring of growth and sexual development.
Maria G Vogiatzi; Karen A Autio; Jeffrey E Mait; Robert Schneider; Martin Lesser; Patricia J Giardina
Related Documents :
10372708 - Bone mineral mass and calcium and phosphate metabolism in young men: relationships with...
11204438 - Interaction between the vitamin d receptor gene and collagen type ialpha1 gene in susce...
24456788 - Use of screws and cement in primary tka with up to 20years follow-up.
11932278 - Bone loss at the femoral neck in premenopausal white women: effects of weight change an...
22054228 - Optimal management of cancer treatment-induced bone loss: considerations for elderly pa...
376198 - Physical and biological aspects of fracture healing with special reference to internal ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1054     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-12     Completed Date:  2006-07-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  462-6     Citation Subset:  IM    
Department of Pediatrics, New York-Presbyterian Hospital / Weill Medical College of Cornell University, New York, New York 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Transfusion
Bone Density*
Bone Diseases, Metabolic / epidemiology,  etiology*
Chelation Therapy
Combined Modality Therapy
Deferoxamine / therapeutic use
Disease Progression
Endocrine System Diseases / drug therapy,  epidemiology,  etiology
Gonadal Steroid Hormones / therapeutic use
Human Growth Hormone / therapeutic use
Hypogonadism / drug therapy,  epidemiology,  etiology
Iron Chelating Agents / therapeutic use
Osteoporosis / epidemiology,  etiology*
Puberty, Delayed / drug therapy,  epidemiology,  etiology
Spine / chemistry
beta-Thalassemia / complications*
Grant Support
5H46 MC00085//PHS HHS; M01-RR06020/RR/NCRR NIH HHS
Reg. No./Substance:
0/Gonadal Steroid Hormones; 0/Iron Chelating Agents; 12629-01-5/Human Growth Hormone; 70-51-9/Deferoxamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quality of life in patients with thalassemia intermedia compared to thalassemia major.
Next Document:  Does heterozygous beta-thalassemia confer a protection against coronary artery disease?